572.76

2.63% 15.03

Regeneron Pharmaceuticals Inc (REGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt REGN? Forum Prognose

Schlusskurs vom Vortag:

$557.73

Offen:

$556.92

24-Stunden-Volumen:

841.19K

Relative Volume:

0.82

Marktkapitalisierung:

$59.65B

Einnahmen:

$14.21B

Nettoeinkommen (Verlust:

$4.46B

KGV:

14.43

EPS:

39.6877

Netto-Cashflow:

$3.56B

1W Leistung:

-1.86%

1M Leistung:

+2.22%

6M Leistung:

+0.24%

1J Leistung:

-43.56%

1-Tages-Spanne:

$553.87

$576.18

1-Wochen-Bereich:

$541.00

$605.00

52-Wochen-Spanne:

$476.49

$1,024.36

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Firmenname

Regeneron Pharmaceuticals Inc

Sektor

Healthcare (1146)

Branche

Biotechnology (639)

Telefon

(914) 847-7000

Adresse

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Mitarbeiter

15,207

Twitter

@regeneron

Nächster Verdiensttermin

2025-08-01

Neueste SEC-Einreichungen

REGN's Discussions on Twitter

Vergleichen Sie REGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REGN Regeneron Pharmaceuticals Inc	572.61	59.11B	14.21B	4.46B	3.56B	39.69
VRTX Vertex Pharmaceuticals Inc	412.63	104.45B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	469.41	60.95B	2.46B	-319.09M	-52.09M	-2.4669
ARGX Argen X Se Adr	804.72	49.23B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.77	35.92B	4.56B	-176.77M	225.30M	-1.7177

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-14	Eingeleitet	Rothschild & Co Redburn	Buy
2025-06-30	Herabstufung	Argus	Buy → Hold
2025-05-30	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-05-14	Hochstufung	Citigroup	Neutral → Buy
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-02-05	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-01-16	Herabstufung	UBS	Buy → Neutral
2024-12-10	Fortgesetzt	BofA Securities	Underperform
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Neutral
2024-09-24	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-03-12	Eingeleitet	Bernstein	Outperform
2024-01-12	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-11-03	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-08-21	Hochstufung	Canaccord Genuity	Hold → Buy
2023-08-21	Bestätigt	Oppenheimer	Perform
2023-06-28	Herabstufung	Canaccord Genuity	Buy → Hold
2023-03-27	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-24	Hochstufung	Jefferies	Hold → Buy
2023-03-23	Hochstufung	Raymond James	Underperform → Mkt Perform
2023-01-30	Hochstufung	Cowen	Market Perform → Outperform
2023-01-20	Hochstufung	JP Morgan	Neutral → Overweight
2022-10-26	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-10-17	Herabstufung	Evercore ISI	Outperform → In-line
2022-09-09	Hochstufung	Jefferies	Underperform → Hold
2022-09-09	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2022-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2022-01-03	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-12-15	Herabstufung	Bernstein	Outperform → Mkt Perform
2021-12-09	Fortgesetzt	Wells Fargo	Overweight
2021-12-07	Fortgesetzt	Cowen	Market Perform
2021-12-06	Eingeleitet	Goldman	Buy
2021-11-19	Fortgesetzt	BMO Capital Markets	Outperform
2021-11-05	Herabstufung	The Benchmark Company	Buy → Hold
2021-06-29	Eingeleitet	H.C. Wainwright	Buy
2021-01-25	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Hochstufung	The Benchmark Company	Hold → Buy
2021-01-08	Hochstufung	Citigroup	Neutral → Buy
2020-10-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Herabstufung	The Benchmark Company	Buy → Hold
2020-07-09	Hochstufung	SunTrust	Hold → Buy
2020-05-26	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-04-28	Herabstufung	Citigroup	Buy → Neutral
2020-04-17	Hochstufung	The Benchmark Company	Hold → Buy
2020-04-08	Eingeleitet	The Benchmark Company	Hold
2020-03-31	Eingeleitet	Wolfe Research	Peer Perform
2020-02-27	Eingeleitet	Barclays	Overweight
2020-02-26	Hochstufung	Canaccord Genuity	Hold → Buy
2020-02-26	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-02-25	Hochstufung	Jefferies	Hold → Buy
2020-02-11	Hochstufung	Argus	Hold → Buy
2019-12-24	Eingeleitet	Raymond James	Mkt Perform
2019-12-16	Herabstufung	Evercore ISI	Outperform → In-line
2019-12-13	Hochstufung	Credit Suisse	Neutral → Outperform
2019-11-12	Eingeleitet	SunTrust	Hold
2019-11-07	Hochstufung	Citigroup	Neutral → Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Neutral
2019-09-23	Hochstufung	Guggenheim	Neutral → Buy

Alle ansehen

Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten

01:00 AM

Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

01:00 AM

10:30 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) Receives Buy Rating from Canaccord Genuity Group - MarketBeat

10:30 AM

10:00 AM

2 Stocks Down 17% and 21% to Buy Right Now - Yahoo Finance

10:00 AM

09:04 AM

Regeneron, Scholar Rock Approvals In Limbo As FDA Hits Novo Plant - insights.citeline.com

09:04 AM

07:26 AM

Canaccord Genuity reiterates Buy rating on Regeneron stock despite EYLEA headwinds - Investing.com

07:26 AM

07:08 AM

Morningstar Investment Management LLC Makes New $608,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

07:08 AM

06:37 AM

Will breakout in Regeneron Pharmaceuticals Inc. lead to full recovery2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com

06:37 AM

06:34 AM

FDA approves Celltrion's Eylea bisoimilar - Eyes On Eyecare

06:34 AM

06:03 AM

Hudson Capital Management LLC Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

06:03 AM

04:49 AM

Vanguard Personalized Indexing Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

04:49 AM

03:09 AM

Top chart patterns to watch in Regeneron Pharmaceuticals Inc.Bull Run & Real-Time Volume Spike Alerts - newser.com

03:09 AM

02:57 AM

Is Regeneron Pharmaceuticals Inc. (RGO) stock ideal for retirement investorsFed Meeting & Weekly High Return Stock Forecasts - newser.com

02:57 AM

01:12 AM

Predicting Regeneron Pharmaceuticals Inc. trend using moving averagesWeekly Profit Summary & Consistent Return Investment Signals - newser.com

01:12 AM

Oct 13, 2025

Regeneron’s Gene Therapy DB-OTO Improves Speech Perception in Children With Otoferlin-Related Hearing Loss - CGTLive®

Oct 13, 2025

Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss - Benzinga

Oct 13, 2025

Citigroup Maintains "Buy" Rating on REGN, Raises Price Target to $660 | REGN Stock News - GuruFocus

Oct 13, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat

Oct 13, 2025

Detecting support and resistance levels for Regeneron Pharmaceuticals Inc.Weekly Gains Summary & High Conviction Buy Zone Picks - newser.com

Oct 13, 2025

How sentiment analysis helps forecast Regeneron Pharmaceuticals Inc. - newser.com

Oct 13, 2025

Why Are Regeneron And Scholar Rock Shares Falling On Monday? - Stocktwits

Oct 13, 2025

Regeneron plans FDA filing based on latest DB-OTO data - The Pharma Letter

Oct 13, 2025

Using data filters to optimize entry into Regeneron Pharmaceuticals Inc.Gap Up & Weekly Setup with High ROI Potential - newser.com

Oct 13, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down on Analyst Downgrade - MarketBeat

Oct 13, 2025

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss - TradingView

Oct 13, 2025